We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Advion Announces Joint Marketing Agreement with Bruker Daltonik GmbH

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Advion BioSystems, Inc. has signed a non-exclusive joint marketing agreement with Bruker Daltonik, GmbH, a wholly owned subsidiary of Bruker Daltonics Inc. to co-promote its TriVersa NanoMate system with Bruker Daltonics mass spectrometers.

The TriVersa NanoMate is an automated nanoelectrospray source that connects to the front of a mass spectrometer. It combines the benefits of liquid chromatography (LC), fraction collection and chip-based infusion in one system. Advion encouraged this agreement to provide greater flexibility to its customers who often have multiple MS systems in their laboratory.

Under the agreement, Advion and Bruker Daltonik GmbH will co-market the TriVersa NanoMate and Bruker MS systems with each company responsible for their individual products. There has been an exchange of instruments to be utilized for applications development and product demonstrations.

Placement in the companies’ demonstration laboratories and applications development for joint product promotion gives the TriVersa NanoMate greater exposure to new MS owners and existing Bruker Daltonics customers. Each company will co-promote their products at industry tradeshows and conferences.

“Advion wants to be the recognized leader in microfluidic systems for mass spectrometry and this agreement is another step in that direction,” said Jack Henion, Advion’s Chief Scientific Officer. “Additionally, Bruker’s market position in the life sciences allows Advion’s customers more flexibility to use its equipment as well as opening greater market potential for future sales in proteomic, biomarker, and metabolism applications.”